EcoDrugPlus

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSTBEG00000005230
Gene Symbol: PSMB2
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSTBEG00000013010
Gene Symbol: PSMB3
1 Cross references
246 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSTBEG00000003244
Gene Symbol: PSMB4
1 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSTBEG00000016334
Gene Symbol: PSMB5
1 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSTBEG00000009196
Gene Symbol: PSMB7
1 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSTBEG00000007794
Gene Symbol: PSMB8
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSTBEG00000012153
Gene Symbol: PSMB9
1 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSTBEG00000000644
Gene Symbol: PSMD2
1 Cross references
222 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4

Ensembl ID : ENSTBEG00000016911
Gene Symbol: PSMD4
1 Cross references
270 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1

Ensembl ID : ENSTBEG00000011564
Gene Symbol: PSMC1
1 Cross references
284 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSTBEG00000013910
Gene Symbol: PSMC2
1 Cross references
227 Possible Orthologues:

Proteasome 26s Subunit, Atpase 5

Ensembl ID : ENSTBEG00000010546
Gene Symbol: PSMC5
1 Cross references
228 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).